C4 Therapeutics (CCCC) PT Raised to $13 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
C4 Therapeutics (CCCC) PT Lowered to $18 at UBS, 'well funded, multiple catalysts - one to watch in '24'
February 27, 2024 12:05 PM ESTUBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $18.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "We have updated our model post C4's 4Q23 EPS, which includes a notably improved cash position vs.... More
